Publications

Complete List of Published Work in PubMed

NLRX1 limits inflammatory neurodegeneration in the anterior visual pathway. Gill, A. J., Smith, M. D., Galleguillos, D., Garton, T., Mace, J. W., Gadani, S. P., ... Calabresi PA., & Gharagozloo, M. (2025).Journal of Neuroinflammation, 22(1), 1-22. 

The Effects of NLY01, a Novel Glucagon-Like Peptide-1 Receptor Agonist, on Cuprizone-Induced Demyelination and Remyelination: Challenges and Future Perspectives.

Gharagozloo M, Galleguillos D, Jank L, Sotirchos ES, Smith MD, Garton T, Kumar S, Hussein O, Potluri S, Taylor M, Siu C, Mace JW, Dawson T, Dawson VL, Lee S, Calabresi PA.

Neurotherapeutics. 2023 Jul;20(4):1229-1240. doi: 10.1007/s13311-023-01390-4. Epub 2023 Jun 9.

Animal models to investigate the effects of inflammation on remyelination in multiple sclerosis.

Gharagozloo M, Mace JW, Calabresi PA.

Front Mol Neurosci. 2022 Nov 3;15:995477. doi: 10.3389/fnmol.2022.995477. eCollection 2022.

Reactive Astrocytes Derived From Human-Induced Pluripotent Stem Cells Suppress Oligodendrocyte Precursor Cell Differentiation.

Smith MD, Chamling X, Gill AJ, Martinez H, Li W, Fitzgerald KC, Sotirchos ES, Moroziewicz D, Bauer L, Paull D, Gharagozloo M, Bhargava P, Zack DJ, Fossati V, Calabresi PA.

Front Mol Neurosci. 2022 May 6;15:874299. doi: 10.3389/fnmol.2022.874299. eCollection 2022.

Retinal pathology in spontaneous opticospinal experimental autoimmune encephalitis mice.

Jin J, Shneyderman M, Smith MD, Gharagozloo M, Sotirchos ES, Calabresi PA.

J Neuroimmunol. 2022 Jun 15;367:577859. doi: 10.1016/j.jneuroim.2022.577859. Epub 2022 Mar 31.

Breaking the barriers to remyelination in multiple sclerosis.

Gharagozloo M, Bannon R, Calabresi PA.

Curr Opin Pharmacol. 2022 Apr;63:102194. doi: 10.1016/j.coph.2022.102194. Epub 2022 Mar 4.

A lymphocyte-microglia-astrocyte axis in chronic active multiple sclerosis.

Absinta M, Maric D, Gharagozloo M, Garton T, Smith MD, Jin J, Fitzgerald KC, Song A, Liu P, Lin JP, Wu T, Johnson KR, McGavern DB, Schafer DP, Calabresi PA, Reich DS.

Nature. 2021 Sep;597(7878):709-714. doi: 10.1038/s41586-021-03892-7. Epub 2021 Sep 8.

Complement component 3 from astrocytes mediates retinal ganglion cell loss during neuroinflammation.

Gharagozloo M, Smith MD, Jin J, Garton T, Taylor M, Chao A, Meyers K, Kornberg MD, Zack DJ, Ohayon J, Calabresi BA, Reich DS, Eberhart CG, Pardo CA, Kemper C, Whartenby KA, Calabresi PA.

Acta Neuropathol. 2021 Nov;142(5):899-915. doi: 10.1007/s00401-021-02366-4. Epub 2021 Sep 6.

Therapeutic Potential of a Novel Glucagon-like Peptide-1 Receptor Agonist, NLY01, in Experimental Autoimmune Encephalomyelitis.

Gharagozloo M, Smith MD, Sotirchos ES, Jin J, Meyers K, Taylor M, Garton T, Bannon R, Lord HN, Dawson TM, Dawson VL, Lee S, Calabresi PA.

Neurotherapeutics. 2021 Jul;18(3):1834

NLRX1 inhibits the early stages of CNS inflammation and prevents the onset of spontaneous autoimmunity.

Gharagozloo M, Mahmoud S, Simard C, Yamamoto K, Bobbala D, Ilangumaran S, Smith MD, Lamontagne A, Jarjoura S, Denault JB, Blais V, Gendron L, Vilariño-Güell C, Sadovnick AD, Ting JP, Calabresi PA, Amrani A, Gris D.

PLoS Biol. 2019 Sep 16;17(9):e3000451. doi: 10.1371/journal.pbio.3000451. eCollection 2019 Sep.

NLRX1 Enhances Glutamate Uptake and Inhibits Glutamate Release by Astrocytes.

Mahmoud S, Gharagozloo M, Simard C, Amrani A, Gris D.

Cells. 2019 Apr 30;8(5):400. doi: 10.3390/cells8050400.